55-month follow-up from the phase III TRIANGLE trial confirms that adding #ibrutinib to immunochemotherapy produces strong rates of failure-free survival and OS in adults with #MCL, at 82% and 88%, respectively, indicating the treatment could be a new SOC: https://ow.ly/BtHJ50ZT4ua